Bulletin of Semashko National Research Institute of Public HealthBulletin of Semashko National Research Institute of Public Health2415-84102415-8429FSSBI «N.A. Semashko National Research Institute of Public Health»281510.69541/NRIPH.2024.04.019РазноеEstimation of the relationship between the mechanism of action of antidepressants and their effectiveness and tolerability (results of an online survey)DrobizhevMikhail Yu.dmyu2001@mail.ruhttps://orcid.org/0000-0002-1536-219XPolskayaElena A.polskaya@neurology.ruhttps://orcid.org/0009-0000-1451-860XN. A. Semashko National Research Institute of Public HealthFederal State Budgetary Scientific Institution «Scientific Center of Neurology»27112024412713207052025Copyright © 2025,2025<p>survey of viewers of the @psyhfarm-tv YouTube channel (89,000 subscribers) on the effectiveness and tolerability of 17 antidepressants showed that selective serotonin reuptake inhibitors, according to respondents, are more likely to help and are well tolerated., Serotonin and norepinephrine reuptake inhibitors were less likely to not help, and receptor-acting antidepressants were more likely to not help than other drugs. Groups of antidepressants with different mechanisms of action differ significantly in effectiveness and tolerability.</p>internetsurveyeffectivenesstolerabilityantidepressantsинтернетопросэффективностьпереносимостьантидепрессанты[Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al., Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357—1366. DOI: 10.1016/S0140-6736(17)32802—7][Natter J, Yokoyama T, Michel B. Relative frequency of drug-induced sleep disorders for 32 antidepressants in a large set of Internet user reviews. Sleep. 2021;44(12):zsab174. DOI: 10.1093/sleep/zsab174][Hughes S, Lacasse J, Fuller RR, Spaulding-Givens J. Adverse effects and treatment satisfaction among online users of four antidepressants. Psychiatry Res. 2017;(255):78—86. DOI: 10.1016/j.psychres.2017.05.021][Stahl S. Essentials of psychopharmacology: Theory and practice. Moscow: GEOTAR-Media; 2022 (in Russian).][American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition. Arlington, VA: American Psychiatric Association; 2013.][Ter Hark SE, Vos CF, Aarnoutse RE, Schene AH, Coenen MJH, Janzing JGE. Biomarkers as predictors of treatment response to tricyclic antidepressants in major depressive disorder: A systematic review. J Psychiatr. Res. 2022;(150):202—213. DOI: 10.1016/j.jpsychires.2022.03.057][Pae Chi-Un. Agomelatine: a new option for treatment of depression? Expert Opin Pharmacother. 2014;15(4):443—7. DOI: 10.1517/14656566.2014.877889][Kokkali M, Pinioti E, Lappas AS, Christodoulou N, Samara MT. Effects of Trazodone on Sleep: A Systematic Review and Meta-analysis. CNS Drugs. 2024;38(10):753—769. DOI: 10.1007/s40263-024-01110-2][Fornaro M, Caiazza C, Rossano F, Cilmi F, Prisco M De, Vieta E, et al., Residual effects of medications for sleep disorders on driving performance: A systematic review and network meta-analysis of randomized controlled trials: NMA driving and hypnotics. Eur. Neuropsychopharmacol. 2024;(81):53—63. DOI: 10.1016/j.euroneuro.2024.01.011][Inoue T, Nishimura A, Sasai K, KitagawaT. Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial. Psychiatry Clin. Neurosci. 2018;(72):103—115. DOI: 10.1111/pcn.12623][Nishimura A, Aritomi Y, Sasai K, Kitagawa T, Mahableshwarkar AR. Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder. Psychiatry Clin. Neurosci. 2018;(72):64—72. DOI: 10.1111/pcn.12565]